The interferon story continues: EORTC CLTG study explores pegylated interferon α-2a’s role in treating mycosis fungoides/Sézary syndrome
British Journal of Dermatology · 2024
DOI: 10.1093/bjd/ljae188 ↗Kurz gefasst
Editorial in der Zeitschrift British Journal of Dermatology, 2024. Verfasst von Rudolf Stadler. Beteiligte Einrichtung: University Department for Dermatology, Venerology, Allergology and Phlebology, Skin Cancer Center, Johannes Wesling Medical Center, UKRUB, University…. Hauptthemen laut MEDLINE: Interferon-alpha, Mycosis Fungoides, Polyethylene Glycols, Skin Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University Department for Dermatology, Venerology, Allergology and Phlebology, Skin Cancer Center, Johannes Wesling Medical Center, UKRUB, University of Bochum, Minden, Germany.
ORCID-Profile: Rudolf Stadler
Zitieren
APA
Stadler, R. (2024). The interferon story continues: EORTC CLTG study explores pegylated interferon α-2a’s role in treating mycosis fungoides/Sézary syndrome. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljae188
Vancouver
Stadler R. The interferon story continues: EORTC CLTG study explores pegylated interferon α-2a’s role in treating mycosis fungoides/Sézary syndrome. British Journal of Dermatology. 2024. doi:10.1093/bjd/ljae188
BibTeX
@article{Stadler2024,
author = {Stadler, Rudolf},
title = {The interferon story continues: EORTC CLTG study explores pegylated interferon α-2a’s role in treating mycosis fungoides/Sézary syndrome},
journal = {British Journal of Dermatology},
year = {2024},
doi = {10.1093/bjd/ljae188}
}
EUVIMED